EUVIMEDEUVIMED entdecken
Crossref

Design and Synthesis of USP1 Inhibitors: Synergistic Antitumor Activity with PARP Inhibitors in Triple-Negative Breast Cancer

Yaxin Teng, Linyu Yang, Haoyue Luo, Minghai Tang, Jialing Song, Liping Gou, Yuzhou Xiao, Xue Cui, Tao Yang iD, Xiaobo Cen iD, Lijuan Chen iD, Yong Li iD und 2 weitere

Journal of Medicinal Chemistry · 14.05.2026 · 69 (9) · 10594-10620

DOI: 10.1021/acs.jmedchem.5c03804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 29.04.2026. Verfasst von Yaxin Teng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Natural and Targeted Small Molecule Drugs, Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China H…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents, Drug Design, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: West China Hospital, Sichuan University, National Natural Science Foundation of China, 2024 Sichuan Provincial Special Program for Leading Scientists in Basic Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntineoplastic AgentsDrug DesignPoly(ADP-ribose) Polymerase InhibitorsUbiquitin-Specific ProteasesHumansAnimalsFemaleCell Line, TumorPhthalazinesCell ProliferationPiperazinesRatsDrug SynergismMiceStructure-Activity RelationshipXenograft Model Antitumor Assays

Substanzen

Antineoplastic AgentsPoly(ADP-ribose) Polymerase InhibitorsUSP1 protein, humanUbiquitin-Specific ProteasesolaparibPhthalazinesPiperazines

Autor:innen und Institutionen

  • Laboratory of Natural and Targeted Small Molecule Drugs, Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
  • Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu 610041, China.
  • National Chengdu Center for Safety Evaluation of Drugs, West China Hospital, Sichuan University, Chengdu 610041, China.
  • West China-Frantier PharmaTech Co., Ltd., Chengdu 610200, China.
  • Innovation Center of Nursing Research and Nursing Key Laboratory of Sichuan Province, State Key Laboratory of Biotherapy and Cancer Center, West ChinaHospital, Sichuan University, West China School of Nursing, Sichuan U…

ORCID-Profile: Tao Yang, Xiaobo Cen, Lijuan Chen, Yong Li, Yinglan Zhao, Zhuang Yang

Förderung

  • West China Hospital, Sichuan University
  • National Natural Science Foundation of China
  • 2024 Sichuan Provincial Special Program for Leading Scientists in Basic Research

Zitieren

APA

Teng, Y., Yang, L., Luo, H., Tang, M., Song, J., Gou, L., Xiao, Y., Cui, X., Yang, T., Cen, X., Chen, L., Li, Y., Zhao, Y., & Yang, Z. (2026). Design and Synthesis of USP1 Inhibitors: Synergistic Antitumor Activity with PARP Inhibitors in Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 69(9), 10594-10620. https://doi.org/10.1021/acs.jmedchem.5c03804

Vancouver

Teng Y, Yang L, Luo H, Tang M, Song J, Gou L, et al. Design and Synthesis of USP1 Inhibitors: Synergistic Antitumor Activity with PARP Inhibitors in Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 2026;69(9):10594-10620. doi:10.1021/acs.jmedchem.5c03804

BibTeX
@article{Teng2026,
  author = {Teng, Yaxin and Yang, Linyu and Luo, Haoyue and Tang, Minghai and Song, Jialing and Gou, Liping and Xiao, Yuzhou and Cui, Xue and Yang, Tao and Cen, Xiaobo and Chen, Lijuan and Li, Yong and Zhao, Yinglan and Yang, Zhuang},
  title = {Design and Synthesis of USP1 Inhibitors: Synergistic Antitumor Activity with PARP Inhibitors in Triple-Negative Breast Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {9},
  pages = {10594--10620},
  doi = {10.1021/acs.jmedchem.5c03804}
}
Kostenlos starten →